German startup New4med announces first cases of its novel Basivertebral Nerve Ablation therapy

German startup New4med announces first cases of its novel Basivertebral Nerve Ablation therapy

Published: 08-07-2024 10:30:00 | By: Pie Kamau | hits: 1654 | Tags:
Europe
Germany
Healthcare
July 2024
Wellness

New4med, a German startup focused on innovative spinal treatments, has announced the successful European market launch of its novel Basivertebral Nerve Ablation (BVNA) therapy.

BVNA is a treatment for vertebrogenic pain, a type of chronic low back pain associated with bony lesions on the vertebral endplates. The system, approved in Europe, is a minimally invasive, implant-free procedure that can be performed on both inpatient and outpatient bases. It uses targeted radiofrequency energy to block the Nervus basivertebralis from transmitting pain signals to the brain, aiming to improve function and provide sustainable relief.

Daniel Seifert, Shareholder and designated CEO, New4med: "By offering BVNA to physicians, we are providing access to this unique treatment for people with vertebrogenic pain in Europe for the first time. Our goal is to make this high-growth therapeutic option available to a broad population of people with chronic low back pain."

The revolutionary Basivertebral Nerve Ablation has tremendous potential to help even more people living with chronic pain. Access to this form of therapy now significantly enhances New4med's treatment spectrum in the field of interventional chronic pain management.

Eric Schaber, Shareholder and Strategy Consultant, New4med: "We will continue to invest in developing our infrastructure to ensure the broadest possible market access and to meet the growing demand for this treatment. This launch is the beginning of a series of new unique extremely innovative approaches that have the chance to revolutionize the current treatment options in spinal surgery."

www.new4med.com

 

Would you like to be featured on Startup Weekly for a free profile interview? Fill in this questionnaire here.

You can also send your columns / opinions / thought leadership pieces / industry insights, survey and reports to info@startup-weekly.com.